Vogenx files for IPO, plans Nasdaq listing under "VOGX"

Vogenx, Inc. filed a Form S-1 with the SEC on July 15, 2026 for an initial public offering of common stock. The company has applied to list on the Nasdaq Capital Market under the symbol "VOGX," and if shares are not approved for listing, it will not complete the offering.¹ The number of shares and price range were not yet specified in the filing.

Vogenx is a clinical-stage biopharmaceutical company focused on therapies for dysfunctions in human metabolism, including post-bariatric hypoglycemia (PBH) and gastroparesis, with its primary objective being to advance mizagliflozin, a selective inhibitor of the sodium-glucose transporter 1 (SGLT1)¹. The drug was discovered by Kissei Pharmaceutical Co., Ltd., with Vogenx obtaining exclusive worldwide rights excluding Japan, Korea and Taiwan in 2021¹.

The company has completed two Phase 2 studies in PBH patients, showing statistically significant reductions in postprandial glucose absorption and insulin secretion, plus improvements in glucose nadir and peak versus placebo or baseline.¹ Vogenx has begun startup activities for a Phase 2b study called EMERGE in PBH and expects to begin screening patients in 2026.¹ The Phase 2b design will test 5 mg and 10 mg doses of mizagliflozin three times daily against placebo, measuring reduction in Level 2 and Level 3 hypoglycemic events.¹

The company also plans a Phase 2 proof-of-concept trial in gastroparesis in 2027 and an IND submission to the FDA in 2027 for GIP-dependent Cushing's Syndrome.¹

On financials, Vogenx reported net losses of $2.2 million and $1.4 million for 2024 and 2025 respectively, with an accumulated deficit of $10.8 million as of December 31, 2025, rising to $11.3 million by March 31, 2026.¹ Since inception the company has raised approximately $11.5 million from investors.¹ The filing also disclosed material weaknesses in internal control over financial reporting.¹